These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 24736661)
1. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen. Patterson KG; Dixon Pittaro JL; Bastedo PS; Hess DA; Haeryfar SM; McCormick JK PLoS One; 2014; 9(4):e95200. PubMed ID: 24736661 [TBL] [Abstract][Full Text] [Related]
2. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414 [TBL] [Abstract][Full Text] [Related]
3. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649 [TBL] [Abstract][Full Text] [Related]
4. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214 [TBL] [Abstract][Full Text] [Related]
5. A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells. Tordsson J; Lavasani S; Ohlsson L; Karlström P; Svedberg H; Abrahmsén L; Brodin T Int J Cancer; 2000 Aug; 87(4):559-68. PubMed ID: 10918198 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750 [TBL] [Abstract][Full Text] [Related]
7. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731 [TBL] [Abstract][Full Text] [Related]
8. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. Hedlund G; Eriksson H; Sundstedt A; Forsberg G; Jakobsen BK; Pumphrey N; Rödström K; Lindkvist-Petersson K; Björk P PLoS One; 2013; 8(10):e79082. PubMed ID: 24194959 [TBL] [Abstract][Full Text] [Related]
9. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598 [TBL] [Abstract][Full Text] [Related]
10. Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SPE-J) from Streptococcus pyogenes. Proft T; Arcus VL; Handley V; Baker EN; Fraser JD J Immunol; 2001 Jun; 166(11):6711-9. PubMed ID: 11359827 [TBL] [Abstract][Full Text] [Related]
11. Construction of Recombinant Single Chain Variable Fragment (ScFv) Antibody Against Superantigen for Immunodetection Using Antibody Phage Display Technology. Singh PK; Agrawal R; Kamboj DV; Singh L Methods Mol Biol; 2016; 1396():207-225. PubMed ID: 26676049 [TBL] [Abstract][Full Text] [Related]
12. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477 [TBL] [Abstract][Full Text] [Related]
13. Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. Papageorgiou AC; Collins CM; Gutman DM; Kline JB; O'Brien SM; Tranter HS; Acharya KR EMBO J; 1999 Jan; 18(1):9-21. PubMed ID: 9878045 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661 [TBL] [Abstract][Full Text] [Related]
16. So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Sundberg EJ; Li Y; Mariuzza RA Curr Opin Immunol; 2002 Feb; 14(1):36-44. PubMed ID: 11790531 [TBL] [Abstract][Full Text] [Related]
17. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729 [TBL] [Abstract][Full Text] [Related]
18. Structure-function studies of T-cell receptor-superantigen interactions. Li H; Llera A; Mariuzza RA Immunol Rev; 1998 Jun; 163():177-86. PubMed ID: 9700510 [TBL] [Abstract][Full Text] [Related]
19. Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens. Sharma P; Wang N; Kranz DM Toxins (Basel); 2014 Jan; 6(2):556-74. PubMed ID: 24476714 [TBL] [Abstract][Full Text] [Related]
20. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1. Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]